Expand Document | Expand Chapter | Full TOC | Printable HTML version
Safety of Medicines - A Guide to Detecting and Reporting Adverse Drug Reactions - Why Health Professionals Need to Take Action
(2002; 16 pages)
Table of Contents
View the documentIntroduction
View the documentGlossary
View the documentThe magnitude of the problem
View the documentWhy postmarketing surveillance and reporting ADR is needed
View the documentWhy pharmacovigilance is needed in every country
View the documentHow voluntary reporting on ADRs can prevent new medicine tragedies from developing
View the documentHow voluntary reporting on ADRs can influence labelling
View the documentWhy health professionals are in the best position to detect and report on ADRs
View the documentHow to recognize ADRs
View the documentWhat should be reported?
View the documentHow to report ADRs?
View the documentReferences
View the documentAcknowledgements
 

What should be reported?

• For “new” drugs - report all suspected reactions, including minor ones. (In many countries drugs are still considered “new” up to five years after marketing authorization);

• For established or well-known drugs - report all serious or unexpected (unusual) suspected ADRs;

• Report if an increased frequency of a given reaction is observed;

• Report all suspected ADRs associated with drug-drug, drug-food or drug-food supplements (including herbal and complementary products) interactions;

• Report ADRs in special fields of interest such as drug abuse and drug use in pregnancy and during lactation;

• Report when suspected ADRs are associated with drug withdrawals;

• Report ADRs occurring from overdose or medication error;

• Report when there is a lack of efficacy or when suspected pharmaceutical defects are observed.

Thus, report all suspected adverse reactions that you consider of clinical importance as soon as possible!

to previous section to next section
 

Last updated: May 3, 2013